Abstract Abstract #5136 Introduction: Prone external beam partial breast irradiation when used for a carefully selected subset of patients has been shown to have excellent long term control and cosmesis (Formenti et al. IJROBP 60(2): 493-504 2004). We used Cone-beam CT (CBCT) to visualize the tumor bed target prior to each daily fraction of partial breast irradiation. The purpose of this study is to measure the residual error in soft tissue positioning after alignment based on skin marks and MV portal imaging for patients treated on a prospective prone APBI study (3000cGy in 5 fractions over 5 days).
 Methods: Twenty-five post-menopausal women with pT1 breast cancer have consented on our NYU partial breast protocol using CBCT. Twenty-three patients have been simulated and treated in the prone position on a specially designed mattress. After initial skin mark setup and alignment, MV portal imaging with shift using the tangent beams eye view was used to optimize setup for the first 6 patients (Group I). For all daily fractions, CBCT was performed with the Varian On-Board Imager kV imaging system with a 35cm field of view and a 2.5mm slice thickness. CBCT was compared with the planning CT to shift the patient and evaluate the residual error in setup. The residual error from CBCT setup after optimal portal imaging was recorded for each patient. For the subsequent 17 patients (Group II), portal imaging was performed without shift to calculate the residual error from CBCT setup representing skin mark setup.
 Results: At the time of this report, 23 patients have been treated with all 5 fractions. The values for the residual error detected after cone-beam CT for Group I (after skin mark set up and portal imaging) and for Group II (after skin mark setup alone) are compared and shown in Table 1.
 Conclusions: In this preliminary study with a small number of patients, the residual error was minimal, around 2 mm. Therefore, for patients immobilized on our customized mattress, a reproducible and accurate prone APBI setup can be achieved with use of CBCT. However, given the very small residual error detected clinicians should be weary of indiscriminant use of CBCT for PBI. Concerns over contralateral breast dose and carcinogenic risk should limit the routine use of CBCT imaging for breast radiotherapy unless larger studies demonstrate improved accuracy of treatment delivery with CBCT.
 
 Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5136.